-
公开(公告)号：US20200024319A1
公开(公告)日：2020-01-23
申请号：US15565376
申请日：2016-05-04
Applicant: AMGEN INC. , Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Ai Ching LIM , Randal Robert KETCHUM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20220144920A1
公开(公告)日：2022-05-12
申请号：US17420231
申请日：2020-01-02
Applicant: AMGEN INC.
Inventor： Jennitte LeAnn STEVENS , Deniz TEMEL , Bram ESTES , Neeraj Jagdish AGRAWAL
IPC: C07K16/00
Abstract: Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.
-
公开(公告)号：US20210139554A1
公开(公告)日：2021-05-13
申请号：US17065395
申请日：2020-10-07
Applicant: Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20190127452A1
公开(公告)日：2019-05-02
申请号：US16099986
申请日：2017-05-11
Applicant: AMGEN INC.
Inventor： Randal Robert KETCHEM , Jeffrey T. MCGREW , Dina A. FOMINA YADLIN , Trent P. MUNRO , Neeraj Jagdish AGRAWAL , Kristine M. DARIS
Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
-
公开(公告)号：US20210017261A1
公开(公告)日：2021-01-21
申请号：US16919032
申请日：2020-07-01
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
Patent Agency Ranking
公开(公告)号：US20190233543A1
公开(公告)日：2019-08-01
申请号：US16338292
申请日：2017-09-28
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Pavel BONDARENKO , Joon Hoi HUH , Andrew NICHOLS , Da REN , Richard SMITH , Riki STEVENSON
CPC classification number: C07K16/40 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N11/14
Abstract: The present invention concerns a method for preparing antigen binding proteins with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
-
公开(公告)号：US20240327486A1
公开(公告)日：2024-10-03
申请号：US18627761
申请日：2024-04-05
Applicant: Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
CPC classification number: C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20230381276A1
公开(公告)日：2023-11-30
申请号：US18072959
申请日：2022-12-01
Applicant: AMGEN INC.
Inventor： Khaled M.K.Z. ALI , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Ian FOLTZ , Zhulun WANG , Darren BATES , Marissa MOCK , Shunsuke TAKENAKA
CPC classification number: A61K38/20 , C12N15/63 , A61P35/00 , C07K16/283 , C07K14/54 , A61K47/6849 , A61K47/6813 , C12N2740/10041
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
公开(公告)号：US20190218279A1
公开(公告)日：2019-07-18
申请号：US16246326
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20240150448A1
公开(公告)日：2024-05-09
申请号：US18545688
申请日：2023-12-19
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
CPC classification number: C07K16/18 , A61K38/2278 , A61P25/06 , C07K16/2869 , A61K2039/545 , C07K2317/34 , C07K2317/565 , C07K2317/92
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.017 seconds)
